|
1
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: The impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Devesa SS, Bray F, Vizcaino AP and Parkin
DM: International lung cancer trends by histologic type:
male:female differences diminishing and adenocarcinoma rates
rising. Int J Cancer. 117:294–299. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sandler A, Gray R, Perry MC, Brahmer J,
Schiller JH, Dowlati A, Lilenbaum R and Johnson DH:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Scagliotti GV, Parikh P, von Pawel J,
Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U,
Digumarti R, Zukin M, et al: Phase III study comparing cisplatin
plus gemcitabine with cisplatin plus pemetrexed in
chemotherapy-naive patients with advanced-stage non-small-cell lung
cancer. J Clin Oncol. 26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schiller JH, Harrington D, Belani CP,
Langer C, Sandler A, Krook J, Zhu J and Johnson DH; Eastern
Cooperative Oncology Group. Comparison of four chemotherapy
regimens for advanced non-small cell lung cancer. N Engl J Med.
346:92–98. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lai C and Lemke G: An extended family of
protein-tyrosine kinase genes differentially expressed in the
vertebrate nervous system. Neuron. 6:691–704. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
O'Bryan JP, Frye RA, Cogswell PC, Neubauer
A, Kitch B, Prokop C, Espinosa R III, Le Beau MM, Earp HS and Liu
ET: axl, a transforming gene isolated from primary human myeloid
leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell
Biol. 11:5016–5031. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lai C, Gore M and Lemke G: Structure,
expression, and activity of Tyro 3, a neural adhesion-related
receptor tyrosine kinase. Oncogene. 9:2567–2578. 1994.PubMed/NCBI
|
|
9
|
Graham DK, Dawson TL, Mullaney DL,
Snodgrass HR and Earp HS: Cloning and mRNA expression analysis of a
novel human protooncogene, c-mer. Cell Growth Differ. 5:647–657.
1994.PubMed/NCBI
|
|
10
|
Heiring C, Dahlbäck B and Muller YA:
Ligand recognition and homophilic interactions in Tyro3: Structural
insights into the Axl/Tyro3 receptor tyrosine kinase family. J Biol
Chem. 279:6952–6958. 2004. View Article : Google Scholar
|
|
11
|
Sasaki T, Knyazev PG, Clout NJ, Cheburkin
Y, Göhring W, Ullrich A, Timpl R and Hohenester E: Structural basis
for Gas6-Axl signalling. EMBO J. 25:80–87. 2006. View Article : Google Scholar
|
|
12
|
Lemke G and Rothlin CV: Immunobiology of
the TAM receptors. Nat Rev Immunol. 8:327–336. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rochlitz C, Lohri A, Bacchi M, Schmidt M,
Nagel S, Fopp M, Fey MF, Herrmann R and Neubauer A: Axl expression
is associated with adverse prognosis and with expression of Bcl-2
and CD34 in de novo acute myeloid leukemia (AML): Results from a
multicenter trial of the Swiss Group for Clinical Cancer Research
(SAKK). Leukemia. 13:1352–1358. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Berclaz G, Altermatt HJ, Rohrbach V,
Kieffer I, Dreher E and Andres AC: Estrogen dependent expression of
the receptor tyrosine kinase axl in normal and malignant human
breast. Ann Oncol. 12:819–824. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Craven RJ, Xu LH, Weiner TM, Fridell YW,
Dent GA, Srivastava S, Varnum B, Liu ET and Cance WG: Receptor
tyrosine kinases expressed in metastatic colon cancer. Int J
Cancer. 60:791–797. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nemoto T, Ohashi K, Akashi T, Johnson JD
and Hirokawa K: Overexpression of protein tyrosine kinases in human
esophageal cancer. Pathobiology. 65:195–203. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rankin EB, Fuh KC, Taylor TE, Krieg AJ,
Musser M, Yuan J, Wei K, Kuo CJ, Longacre TA and Giaccia AJ: AXL is
an essential factor and therapeutic target for metastatic ovarian
cancer. Cancer Res. 70:195–203. 2010. View Article : Google Scholar
|
|
18
|
Sainaghi PP, Castello L, Bergamasco L,
Galletti M, Bellosta P and Avanzi GC: Gas6 induces proliferation in
prostate carcinoma cell lines expressing the Axl receptor. J Cell
Physiol. 204:36–44. 2005. View Article : Google Scholar
|
|
19
|
Ito T, Ito M, Naito S, Ohtsuru A, Nagayama
Y, Kanematsu T, Yamashita S and Sekine I: Expression of the Axl
receptor tyrosine kinase in human thyroid carcinoma. Thyroid.
9:563–567. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hutterer M, Knyazev P, Abate A, Reschke M,
Maier H, Stefanova N, Knyazeva T, Barbieri V, Reindl M, Muigg A, et
al: Axl and growth arrest-specific gene 6 are frequently
overexpressed in human gliomas and predict poor prognosis in
patients with glioblastoma multiforme. Clin Cancer Res. 14:130–138.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sun WS, Fujimoto J and Tamaya T:
Coexpression of growth arrest-specific gene 6 and receptor tyrosine
kinases Axl and Sky in human uterine endometrial cancers. Ann
Oncol. 14:898–906. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gustafsson A, Martuszewska D, Johansson M,
Ekman C, Hafizi S, Ljungberg B and Dahlbäck B: Differential
expression of Axl and Gas6 in renal cell carcinoma reflecting tumor
advancement and survival. Clin Cancer Res. 15:4742–4749. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wimmel A, Glitz D, Kraus A, Roeder J and
Schuermann M: Axl receptor tyrosine kinase expression in human lung
cancer cell lines correlates with cellular adhesion. Eur J Cancer.
37:2264–2274. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Linger RM, Keating AK, Earp HS and Graham
DK: Taking aim at Mer and Axl receptor tyrosine kinases as novel
therapeutic targets in solid tumors. Expert Opin Ther Targets.
14:1073–1090. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shieh YS, Lai CY, Kao YR, Shiah SG, Chu
YW, Lee HS and Wu CW: Expression of axl in lung adenocarcinoma and
correlation with tumor progression. Neoplasia. 7:1058–1064. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Abe Y, Hashimoto S and Horie T: Curcumin
inhibition of inflammatory cytokine production by human peripheral
blood monocytes and alveolar macrophages. Pharmacol Res. 39:41–47.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Oyama Y, Masuda T, Nakata M, Chikahisa L,
Yamazaki Y, Miura K and Okagawa M: Protective actions of
5′-n-alkylated curcumins on living cells suffering from oxidative
stress. Eur J Pharmacol. 360:65–71. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Park W, Amin AR, Chen ZG and Shin DM: New
perspectives of curcumin in cancer prevention. Cancer Prev Res
(Phila). 6:387–400. 2013. View Article : Google Scholar
|
|
29
|
Sharma RA, Euden SA, Platton SL, Cooke DN,
Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer
SM, et al: Phase I clinical trial of oral curcumin: Biomarkers of
systemic activity and compliance. Clin Cancer Res. 10:6847–6854.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dhillon N, Aggarwal BB, Newman RA, Wolff
RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V and Kurzrock
R: Phase II trial of curcumin in patients with advanced pancreatic
cancer. Clin Cancer Res. 14:4491–4499. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Stitt TN, Conn G, Gore M, Lai C, Bruno J,
Radziejewski C, Mattsson K, Fisher J, Gies DR, Jones PF, et al: The
anticoagulation factor protein S and its relative, Gas6, are
ligands for the Tyro 3/Axl family of receptor tyrosine kinases.
Cell. 80:661–670. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Varnum BC, Young C, Elliott G, Garcia A,
Bartley TD, Fridell YW, Hunt RW, Trail G, Clogston C, Toso RJ, et
al: Axl receptor tyrosine kinase stimulated by the vitamin
K-dependent protein encoded by growth-arrest-specific gene 6.
Nature. 373:623–626. 1995. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
McGuire WP, Hoskins WJ, Brady MF, Kucera
PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M:
Cyclophosphamide and cisplatin compared with paclitaxel and
cisplatin in patients with stage III and stage IV ovarian cancer. N
Engl J Med. 334:1–6. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Stordal B, Pavlakis N and Davey R: A
systematic review of platinum and taxane resistance from bench to
clinic: An inverse relationship. Cancer Treat Rev. 33:688–703.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Linger RM, Keating AK, Earp HS and Graham
DK: TAM receptor tyrosine kinases: Biologic functions, signaling,
and potential therapeutic targeting in human cancer. Adv Cancer
Res. 100:35–83. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ye X, Li Y, Stawicki S, Couto S,
Eastham-Anderson J, Kallop D, Weimer R, Wu Y and Pei L: An anti-Axl
monoclonal antibody attenuates xenograft tumor growth and enhances
the effect of multiple anticancer therapies. Oncogene.
29:5254–5264. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li Y, Ye X, Tan C, Hongo JA, Zha J, Liu J,
Kallop D, Ludlam MJ and Pei L: Axl as a potential therapeutic
target in cancer: Role of Axl in tumor growth, metastasis and
angiogenesis. Oncogene. 28:3442–3455. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sethi G and Tergaonkar V: Potential
pharmacological control of the NF-κB pathway. Trends Pharmacol Sci.
30:313–321. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dorai T, Gehani N and Katz A: Therapeutic
potential of curcumin in human prostate cancer. II Curcumin
inhibits tyrosine kinase activity of epidermal growth factor
receptor and depletes the protein. Mol Urol. 4:1–6. 2000.PubMed/NCBI
|
|
40
|
Seol DW, Chen Q and Zarnegar R:
Transcriptional activation of the hepatocyte growth factor receptor
(c-met) gene by its ligand (hepatocyte growth factor) is mediated
through AP-1. Oncogene. 19:1132–1137. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sharma RA, Ireson CR, Verschoyle RD, Hill
KA, Williams ML, Leuratti C, Manson MM, Marnett LJ, Steward WP and
Gescher A: Effects of dietary curcumin on glutathione S-transferase
and malondialdehyde-DNA adducts in rat liver and colon mucosa:
Relationship with drug levels. Clin Cancer Res. 7:1452–1458.
2001.PubMed/NCBI
|
|
42
|
Townsend D and Tew K: Cancer drugs,
genetic variation and the glutathione-S-transferase gene family. Am
J Pharmacogenomics. 3:157–172. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang Z, Lee JC, Lin L, Olivas V, Au V,
LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, et al:
Activation of the AXL kinase causes resistance to EGFR-targeted
therapy in lung cancer. Nat Genet. 44:852–860. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rho JK, Choi YJ, Kim SY, Kim TW, Choi EK,
Yoon SJ, Park BM, Park E, Bae JH, Choi CM, et al: MET and AXL
inhibitor NPS-1034 exerts efficacy against lung cancer cells
resistant to EGFR kinase inhibitors because of MET or AXL
activation. Cancer Res. 74:253–262. 2014. View Article : Google Scholar
|
